\-\ Texto\\:\\ \ \(0\)\
\-\ \\â\\€\\¢\\ elevated\\ liver\\ enzymes\\;\ \(0\)\
\-\ \\â\\€\\¢\\ elevated\\ total\\ bilirubin\\;\ \(0\)\
\-\ \\+\\ perinuclear\\ antineutrophil\\ cytoplasmic\\ antibodies\\ \\(panca\\)\ \(0\)\
\-\ medications\\ for\\ itching\\ and\\ infection\\;\\ vitamin\\ supplements\\ for\\ nutritional\\ deficiency\\;\\ the\\ patient\\ is\\ awaiting\\ liver\\ transplant\\.\ \(0\)\
\-\ contast\\-enhanced\\ axial\\ ct\\ image\\ demonstrates\\ nodular\\ appearance\\ of\\ the\\ surface\\ of\\ the\\ liver\\,\\ atrophy\\ of\\ the\\ lateral\\ and\\ posterior\\ segments\\,\\ hypertrophy\\ of\\ the\\ caudate\\ lobe\\,\\ and\\ overall\\ rounded\\ appearance\\ to\\ the\\ liver\\,\\ all\\ concerning\\ for\\ cirrhosis\\.\\ \\ the\\ spleen\\ is\\ enlarged\\.\\ \\ there\\ is\\ thickening\\ of\\ the\\ wall\\ of\\ the\\ colon\\.\\ \\ mrcp\\ image\\ \\(obtained\\ 5\\ years\\ earlier\\)demonstrates\\ a\\ beaded\\ appearance\\ to\\ the\\ intrahepatic\\ ducts\\.\ \(0\)\
\-\ primary\\ sclerosing\\ cholangitis\\ with\\ ulcerative\\ colitis\ \(0\)\
\-\ sclerosing\\ cholangitis\\ with\\ ulcerative\\ colitis\ \(0\)\
\-\ secondary\\ cholangitis\\ with\\ infectious\\ colitis\ \(0\)\
\-\ \\ \\(eg\\.\\ aids\\)\ \(0\)\
\-\ diffuse\\ cholangiocarcinoma\ \(0\)\
\-\ pseudocirrhosis\\ from\\ metastatic\\ disease\ \(0\)\
\-\ 47\\ y\\.o\\.\\ man\\ with\\ vague\\ abdominal\\ pain\\ and\\ jaundice\ \(1\)\
\-\ charatcharoenwitthaya\\ p\\,\\ lindor\\ kd\\ \\(feb\\ 2006\\)\\.\\ \\"primary\\ sclerosing\\ cholangitis\\:\\ diagnosis\\ and\\ management\\"\\.\\ curr\\ gastroenterol\\ rep\\ 8\\ \\(1\\)\\:\\ 75\\â\\€\\“82\\.\ \(0\)\
\-\ dodd\\ et\\.\\ al\\.\\,\\ end\\-stage\\ primary\\ sclerosing\\ cholangitis\\:\\ ct\\ findings\\ of\\ hepatic\\ morphology\\ in\\ 36\\ patients\\.\\ \\ radiology\\ 1999\\;\\ 211\\:357\\-362\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cholangitis\\:\\ 0\\.1409366148404638\ \(0\)\
\-\ sclerosing\\:\\ 0\\.10108636616545871\ \(0\)\
\-\ colitis\\:\\ 0\\.0703257605838211\ \(0\)\
\-\ liver\\:\\ 0\\.05892443021665447\ \(0\)\
\-\ ulcerative\\:\\ 0\\.05448222593980024\ \(0\)\
\-\ \\;\\:\\ 0\\.050635529711314846\ \(0\)\
\-\ perinuclear\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ panca\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ contast\\-enhanced\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ pseudocirrhosis\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ charatcharoenwitthaya\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ lindor\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ 75\\â\\€\\“82\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ dodd\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ 211\\:357\\-362\\:\\ 0\\.04407759211983249\ \(0\)\
\-\ antineutrophil\\:\\ 0\\.038584530676491945\ \(0\)\
\-\ primary\\:\\ 0\\.037970763943435445\ \(0\)\
\-\ curr\\:\\ 0\\.03714612031423304\ \(0\)\
\-\ rep\\:\\ 0\\.03714612031423304\ \(0\)\
\-\ appearance\\:\\ 0\\.03665859865101962\ \(0\)\
\-\ gastroenterol\\:\\ 0\\.03603040255766199\ \(0\)\
\-\ itching\\:\\ 0\\.035118794773692216\ \(0\)\
\-\ kd\\:\\ 0\\.035118794773692216\ \(0\)\
\-\ supplements\\:\\ 0\\.034348041374555924\ \(0\)\
\-\ beaded\\:\\ 0\\.03368038441143331\ \(0\)\
\-\ cytoplasmic\\:\\ 0\\.03309146923315139\ \(0\)\
\-\ nutritional\\:\\ 0\\.03256466665486226\ \(0\)\
\-\ mrcp\\:\\ 0\\.03125284533252481\ \(0\)\
\-\ antibodies\\:\\ 0\\.0308823054717562\ \(0\)\
\-\ al\\.\\:\\ 0\\.03053734111432144\ \(0\)\
\-\ end\\-stage\\:\\ 0\\.03053734111432144\ \(0\)\
\-\ elevated\\:\\ 0\\.02899316361359063\ \(0\)\
\-\ awaiting\\:\\ 0\\.028854979931215375\ \(0\)\
\-\ caudate\\:\\ 0\\.028622379853040912\ \(0\)\
\-\ feb\\:\\ 0\\.028400121040186743\ \(0\)\
\-\ enzymes\\:\\ 0\\.02778710942972508\ \(0\)\
\-\ cholangiocarcinoma\\:\\ 0\\.026907656097406762\ \(0\)\
\-\ aids\\:\\ 0\\.02674891260583386\ \(0\)\
\-\ image\\:\\ 0\\.02669189166297601\ \(0\)\
\-\ bilirubin\\:\\ 0\\.025759783889184262\ \(0\)\
\-\ eg\\:\\ 0\\.025633194849262807\ \(0\)\
\-\ jaundice\\:\\ 0\\.02550973178631095\ \(0\)\
\-\ morphology\\:\\ 0\\.02550973178631095\ \(0\)\
\-\ vitamin\\:\\ 0\\.025156643950241184\ \(0\)\
\-\ cirrhosis\\:\\ 0\\.025156643950241184\ \(0\)\
\-\ intrahepatic\\:\\ 0\\.025156643950241184\ \(0\)\
\-\ 2006\\:\\ 0\\.024618490629279358\ \(0\)\
\-\ ducts\\:\\ 0\\.02451747709269176\ \(0\)\
\-\ 1999\\:\\ 0\\.024226132552071886\ \(0\)\
\-\ segments\\:\\ 0\\.024040926193670136\ \(0\)\
\-\ transplant\\:\\ 0\\.02360586930872199\ \(0\)\
\-\ deficiency\\:\\ 0\\.023054129022877665\ \(0\)\
\-\ spleen\\:\\ 0\\.022980053593951957\ \(0\)\
\-\ vague\\:\\ 0\\.022980053593951957\ \(0\)\
\-\ concerning\\:\\ 0\\.022423925418400836\ \(0\)\
\-\ 47\\:\\ 0\\.022423925418400836\ \(0\)\
\-\ \\+\\:\\ 0\\.022043995883511226\ \(0\)\
\-\ atrophy\\:\\ 0\\.022043995883511226\ \(0\)\
\-\ hypertrophy\\:\\ 0\\.0219833890808495\ \(0\)\
\-\ p\\:\\ 0\\.02192350812561592\ \(0\)\
\-\ 36\\:\\ 0\\.02141459465406621\ \(0\)\
\-\ overall\\:\\ 0\\.021255851162493313\ \(0\)\
\-\ earlier\\:\\ 0\\.021101992869159543\ \(0\)\
\-\ rounded\\:\\ 0\\.02105174118989203\ \(0\)\
\-\ medications\\:\\ 0\\.019057860590105197\ \(0\)\
\-\ surface\\:\\ 0\\.018860466535236257\ \(0\)\
\-\ demonstrates\\:\\ 0\\.01866621201653186\ \(0\)\
\-\ total\\:\\ 0\\.01839859993458118\ \(0\)\
\-\ infectious\\:\\ 0\\.01836927433731919\ \(0\)\
\-\ \\(\\:\\ 0\\.018059043156096515\ \(0\)\
\-\ radiology\\:\\ 0\\.018057558684448513\ \(0\)\
\-\ nodular\\:\\ 0\\.017922049035559558\ \(0\)\
\-\ hepatic\\:\\ 0\\.01784247175903006\ \(0\)\
\-\ \\)\\:\\ 0\\.017838442302832627\ \(0\)\
\-\ et\\:\\ 0\\.01748699215061141\ \(0\)\
\-\ \\:\\:\\ 0\\.016954122239859974\ \(0\)\
\-\ colon\\:\\ 0\\.016779664549111697\ \(0\)\
\-\ management\\:\\ 0\\.016122657217278208\ \(0\)\
\-\ 8\\:\\ 0\\.01597558779124674\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.015670143515958877\ \(0\)\
\-\ obtained\\:\\ 0\\.01518933050371921\ \(0\)\
\-\ enlarged\\:\\ 0\\.014578105351920032\ \(0\)\
\-\ thickening\\:\\ 0\\.014483122848466758\ \(0\)\
\-\ diffuse\\:\\ 0\\.012935037101876575\ \(0\)\
\-\ years\\:\\ 0\\.012546215685092413\ \(0\)\
\-\ 5\\:\\ 0\\.012500802112220818\ \(0\)\
\-\ infection\\:\\ 0\\.012420082870364035\ \(0\)\
\-\ wall\\:\\ 0\\.01237579560119373\ \(0\)\
\-\ y\\.o\\:\\ 0\\.012331897162933501\ \(0\)\
\-\ axial\\:\\ 0\\.012193957380339357\ \(0\)\
\-\ all\\:\\ 0\\.012084617447156455\ \(0\)\
\-\ ct\\:\\ 0\\.011953036533920429\ \(0\)\
\-\ secondary\\:\\ 0\\.011945149832544038\ \(0\)\
\-\ lobe\\:\\ 0\\.01149662673961767\ \(0\)\
\-\ patients\\:\\ 0\\.011057872996830129\ \(0\)\
\-\ for\\:\\ 0\\.010936622229640727\ \(0\)\
\-\ metastatic\\:\\ 0\\.010755547018080451\ \(0\)\
\-\ abdominal\\:\\ 0\\.010679596190610577\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.010500675188159085\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.010298747509911214\ \(0\)\
\-\ 1\\:\\ 0\\.010166631839798535\ \(0\)\
\-\ man\\:\\ 0\\.010104659215449997\ \(0\)\
\-\ posterior\\:\\ 0\\.009848192743512243\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0098110966539021\ \(0\)\
\-\ lateral\\:\\ 0\\.009233340228122751\ \(0\)\
\-\ findings\\:\\ 0\\.009094184678949799\ \(0\)\
\-\ is\\:\\ 0\\.008434361675770885\ \(0\)\
\-\ \\,\\:\\ 0\\.00812130196551862\ \(0\)\
\-\ disease\\:\\ 0\\.006983687706078521\ \(0\)\
\-\ the\\:\\ 0\\.00691246423518129\ \(0\)\
\-\ there\\:\\ 0\\.006358577782324943\ \(0\)\
\-\ from\\:\\ 0\\.006332178565771062\ \(0\)\
\-\ pain\\:\\ 0\\.005218040837653674\ \(0\)\
\-\ and\\:\\ 0\\.004500225143305461\ \(0\)\
\-\ patient\\:\\ 0\\.00428295965458194\ \(0\)\
\-\ to\\:\\ 0\\.0042706810844298625\ \(0\)\
\-\ of\\:\\ 0\\.004077633027929595\ \(0\)\
\-\ with\\:\\ 0\\.002340083521797795\ \(0\)\
\-\ \\.\\:\\ 0\\.0021299721658407764\ \(0\)\
\-\ in\\:\\ 0\\.0021069861507012747\ \(0\)\
\-\ a\\:\\ 0\\.0019829990090930063\ \(0\)\
